References
- Moley JF. Medullary thyroid cancer. Surg Clin North Am 1995;75:405–20.
- Ball DW. Medullary thyroid carcinoma. Thyroid cancer. A comprehensive guide to clinical management. Wartofsky L. 2000;42:365.
- Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, . Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008;7:1001–6. Epub 2008 Apr 29.
- Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, . Germline mutation of the ret protoonco-gene in MEN type 2A. Nature 1993;363:458–60.
- Brierley JD, Tsang RW. External radiation therapy of medullary thyroid cancer. Thyroid cancer. A comprehensive guide to clinical management. Wartofsky L, Van Nostrand D. 2006;72:605–7.
- Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, . Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403–10.
- Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, . Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714–9. Epub 2008 Jun 9.
- Lanzi C, Cassinelli G, Nicolini V, Zunino F. Targeting RET for thyroid cancer therapy. Biochem Pharmacol 2009;77:297–309. Epub 2008 Nov 6.
- Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, . Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007;282:29230–40. Epub 2007 Jul 30.
- Henderson YC, Ahn SH, Kang Y, Clayman GL. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res 2008;14:4908–14.
- Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009.
- Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, . Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009.
- Ball DW. Medullary thyroid cancer: Therapeutic targets and molecular markers. Curr Opin Oncol 2007;19:18–23.